ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

TSVT 2seventy bio Inc

3.965
-0.165 (-4.00%)
Last Updated: 15:22:21
Delayed by 15 minutes
Share Name Share Symbol Market Type
2seventy bio Inc NASDAQ:TSVT NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.165 -4.00% 3.965 3.96 3.97 4.03 3.9284 4.03 95,980 15:22:21

2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024

03/05/2024 12:00pm

Business Wire


2seventy bio (NASDAQ:TSVT)
Historical Stock Chart


From Apr 2024 to Jun 2024

Click Here for more 2seventy bio Charts.

2seventy bio, Inc. (Nasdaq: TSVT) will announce its first quarter 2024 financial results on Wednesday, May 8, 2024. A conference call and webcast will be held at 8:00 a.m. ET.

Participants can access the conference call live via webcast which will be available on the Investors and Media page of the company’s website at https://ir.2seventybio.com. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. It is recommended that participants join 10 minutes prior to the event’s start. A replay of the call will be available on the 2seventy bio website following the completion of the call.

About 2seventy bio

Our name, 2seventy bio, reflects why we do what we do - TIME. Cancer rips time away, and our goal is to work at the maximum speed of translating human thought into action – 270 miles per hour – to give the people we serve more time. With a deep understanding of the human body’s immune response to tumor cells and how to translate cell therapies into practice, we’re applying this knowledge to deliver the first FDA-approved CAR T cell therapy for multiple myeloma to as many patients as possible. Importantly, we remain focused on accomplishing our mission by staying genuine and authentic to our “why” and keeping our people and culture top of mind every day.

For more information, visit www.2seventybio.com.

Follow 2seventy bio on social media: X (Twitter) and LinkedIn.

2seventy bio is a trademark of 2seventy bio, Inc.

Investors: Vicki Eatwell, CFO vicki.eatwell@2seventybio.com Jenn Snyder Jenn.snyder@2seventybio.com Media: Jenn Snyder Jenn.snyder@2seventybio.com

1 Year 2seventy bio Chart

1 Year 2seventy bio Chart

1 Month 2seventy bio Chart

1 Month 2seventy bio Chart

Your Recent History

Delayed Upgrade Clock